Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRED-HF: Withdrawal of Therapy in Recovered Heart Failure
NCT02859311Phase 4Unknown
- Sponsor
- Royal Brompton and Harefield hospitals
- Start
- Apr 2016
- Primary completion
- Aug 2018
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in dilated cardiomyopathy (DCM) and heart failure (HF) (2 arms), sponsored by Royal Brompton and Harefield hospitals. Primary endpoint: Relapse in heart failure at 6 months. Status: unknown.
02
Conditions
dilated cardiomyopathy (DCM)heart failure (HF)
Beyond the preview
Go deeper on NCT02859311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859311.